Figure 5: The pre-(above) and post-treatment (below) CT imaging(A) and hybrid 99mTc-HL91 SPECT imaging(B) in a breast cancer patient with nonresponse to neoadjuvant chemotherapy. After neoadjuvant chemotherapy, the radioactivity of 99mTc-HL91 in breast cancer area was no significant difference, with the tumor to non- tumor HL91 radioactivity ratio was 2.15(pre-treatment) and 2.07(post-treatment) respectively.